On April 2, 2025, the United States announced what it called "Liberation Day" — a sweeping set of tariffs targeting imports from over 60 countries. China bore the heaviest blow at 145%, but India was not spared: a 26% reciprocal tariff now applies to the vast majority of Indian goods entering the United States.
For India, this moment is simultaneously a threat and an opening. Understanding which side of that ledger dominates requires looking carefully at the structure of India's exports, its position in global supply chains, and the geopolitical chess game being played out between Washington, Beijing, and New Delhi.
What India Actually Exports to the US
The United States is India's largest single-country export destination, absorbing roughly 18% of India's total merchandise exports. The top categories are pharmaceuticals, petroleum products, gems and jewellery, engineering goods, and textiles. Each of these faces different levels of exposure.
Pharmaceuticals are India's most critical export and also its most protected. Indian generic drug manufacturers supply roughly 47% of all generic prescriptions dispensed in the US. This dependence is so embedded in the American healthcare system that a sharp tariff on Indian pharma would translate almost immediately into higher drug prices for American consumers — a politically toxic outcome. The Trump administration has signalled that pharmaceuticals may receive separate treatment, though no formal carve-out has been announced.
Gems and jewellery, on the other hand, face immediate pressure. India processes the majority of the world's diamonds and much of that finished product flows to US consumers. A 26% tariff makes Indian jewellery significantly less competitive against alternatives from countries with lower or zero tariffs.
"India's export basket to the US is not monolithic. Pharma will likely survive; labour-intensive goods like textiles and gems face a genuine squeeze." — Trade economist, ICRIER
The China Displacement Opportunity
Here is where India's story gets more interesting. With Chinese exports now facing a 145% tariff wall, American importers are scrambling for alternative suppliers. Categories where China has historically dominated — electronics assembly, furniture, certain chemicals, and apparel — are now suddenly open for renegotiation.
India has been positioning for exactly this shift for several years. The Production Linked Incentive (PLI) schemes launched between 2020 and 2023 were explicitly designed to build manufacturing capacity in electronics, textiles, pharmaceuticals, and food processing. Apple's decision to shift iPhone assembly to India is the most visible signal of this trend.
But the scale of China's displacement is staggering. China exported roughly $440 billion of goods to the US in 2024. Even capturing 5–10% of that redirected trade would be transformative for India. The constraint is not demand — it is India's supply-side readiness: infrastructure, logistics, labour productivity, and regulatory ease of doing business.
What Happens to the Rupee
Currency markets have already begun pricing in the uncertainty. The Indian Rupee weakened past 84.5 to the dollar in the days following the tariff announcement, as risk-off sentiment swept through emerging market currencies broadly.
Two forces are pulling in opposite directions. On the negative side: a slowdown in export earnings, potential capital outflows as global investors reduce EM exposure, and higher import costs for oil (priced in dollars). On the positive side: if India is seen as the primary beneficiary of China's displacement, FDI inflows could accelerate and provide a counterbalancing bid for the rupee.
The RBI has significant reserves — over $640 billion as of early 2025 — and will likely intervene to prevent disorderly depreciation. But the central bank will also be wary of using reserves aggressively if the uncertainty persists through the year.
The Geopolitical Dimension
India's response to the tariffs has been notably measured. Rather than retaliating immediately (as the EU and China did), New Delhi signalled willingness to negotiate a bilateral trade deal with Washington. This is a deliberate strategic choice.
India has spent the better part of a decade carefully positioning itself as a partner to the US without becoming a formal ally — maintaining strategic autonomy while deepening economic ties. The tariff crisis is, paradoxically, an opportunity to formalise what has been an increasingly close but informal relationship.
If India can negotiate even a partial carve-out or a fast-tracked bilateral trade agreement, it would gain a structural advantage over other emerging market competitors. Vietnam, Bangladesh, and Mexico are all competing for the same redirected manufacturing orders. The country that secures preferential access to the US market first wins.
The Bottom Line for India
The net effect of the US tariff war on India is likely to be mildly negative in the short run and potentially positive in the medium run — but this second outcome is not guaranteed. It depends on:
- Whether India can negotiate a bilateral trade deal or pharma carve-out with the US
- Whether Indian manufacturers can actually scale up to absorb displaced China orders
- Whether global growth holds up or a US-triggered recession destroys demand altogether
- Whether the rupee depreciation remains orderly or becomes disruptive
For investors and policymakers, the next 90 days — during which many of the tariffs are reportedly under review — are the critical window. India's ability to move quickly at the diplomatic and industrial level will determine whether 2025 is remembered as the year India broke through, or the year it got caught in someone else's crossfire.
The window is open. Whether India walks through it depends less on what Washington does next, and more on what New Delhi does in response.